| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VASCN.2019.04.001 |
| P698 | PubMed publication ID | 30999054 |
| P2093 | author name string | Donglin Guo | |
| Stephen Jenkinson | |||
| P2860 | cites work | The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. | Q51711166 |
| Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents | Q83027521 | ||
| A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias | Q87375537 | ||
| An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel | Q89149614 | ||
| Tricyclic antidepressant overdose: a review | Q24671973 | ||
| The role of late I Na in development of cardiac arrhythmias | Q26823149 | ||
| The cardiac sodium channel: gating function and molecular pharmacology | Q28207195 | ||
| Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 | ||
| Hypoxia and persistent sodium current. | Q30331627 | ||
| Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data | Q31136281 | ||
| Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure | Q33936393 | ||
| Molecular and cellular mechanisms of cardiac arrhythmias | Q34175373 | ||
| Neurotoxins and their binding areas on voltage-gated sodium channels | Q34232755 | ||
| Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties | Q34339876 | ||
| Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit | Q34384573 | ||
| Late cardiac sodium current can be assessed using automated patch-clamp | Q34433632 | ||
| The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. | Q34658210 | ||
| Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development | Q35095735 | ||
| Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation. | Q35698299 | ||
| Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome | Q36387356 | ||
| The role of the persistent Na(+) current during cardiac ischemia and hypoxia | Q36474191 | ||
| The cardiac persistent sodium current: an appealing therapeutic target? | Q37028768 | ||
| Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine | Q37159534 | ||
| Computational approaches to understand cardiac electrophysiology and arrhythmias | Q37174582 | ||
| SCN5A channelopathies--an update on mutations and mechanisms | Q37332770 | ||
| Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967 | Q37333069 | ||
| The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation | Q38464750 | ||
| On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex | Q38464799 | ||
| Late sodium current: A mechanism for angina, heart failure, and arrhythmia | Q38532814 | ||
| A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm. | Q38546437 | ||
| The cardiac sodium channel gene SCN5A and its gene product NaV1.5: Role in physiology and pathophysiology. | Q38585131 | ||
| Use-dependent block of cardiac late Na(+) current by ranolazine | Q40845713 | ||
| Relation between veratridine reaction dynamics and macroscopic Na current in single cardiac cells | Q42258057 | ||
| Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. | Q46916241 | ||
| Cardiac sodium channel antagonism - Translation of preclinical in vitro assays to clinical QRS prolongation | Q47773798 | ||
| P304 | page(s) | 106575 | |
| P577 | publication date | 2019-04-15 | |
| P1433 | published in | Journal of Pharmacological and Toxicological Methods | Q15724529 |
| P1476 | title | Simultaneous assessment of compound activity on cardiac Nav1.5 peak and late currents in an automated patch clamp platform | |
| P478 | volume | 99 |
| Q99711278 | Curcumin, a Multi-Ion Channel Blocker That Preferentially Blocks Late Na+ Current and Prevents I/R-Induced Arrhythmias |
| Q96952596 | Eleutheroside B, a selective late sodium current inhibitor, suppresses atrial fibrillation induced by sea anemone toxin II in rabbit hearts |
| Q98196750 | Inhibition of the INa/K and the activation of peak INa contribute to the arrhythmogenic effects of aconitine and mesaconitine in guinea pigs |
Search more.